GLYC - GlycoMimetics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.95
+0.31 (+2.66%)
At close: 4:00PM EST

11.95 0.00 (0.00%)
After hours: 4:10PM EST

Stock chart is not supported by your current browser
Previous Close11.64
Open11.49
Bid11.49 x 800
Ask13.47 x 1100
Day's Range11.24 - 11.98
52 Week Range10.93 - 26.05
Volume206,288
Avg. Volume280,253
Market Cap515.49M
Beta (3Y Monthly)3.70
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire10 days ago

    Report: Developing Opportunities within Stryker, Anavex Life Sciences, Engility, Baker Hughes, a GE company, GlycoMimetics, and HCP — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire15 days ago

    GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements

    ROCKVILLE, Md.-- -- Continued to select new clinical sites and ready previously-selected sites in the U.S., Europe, Canada and Australia for the company-sponsored Phase 3 pivotal trial in relapsed/refractory AML; study now open for enrollment Received notice of Japanese patent issuance in August for uproleselan composition of matter as well as pharmaceutical formulations, expiring in December 2032 ...

  • Business Wire15 days ago

    GlycoMimetics to Present Analyses from Phase 1/2 AML Trial of Uproleselan at 60th ASH Meeting

    ROCKVILLE, Md.-- -- New and updated clinical outcomes data and subgroup analyses continue to demonstrate potential benefit of treatment with uproleselan when added to chemotherapy 69 percent of evaluable patients with relapsed/refractory acute myeloid leukemia and 56 percent of evaluable patients with newly diagnosed AML achieved MRD-negative remission in clinical trial Correlation of E-selectin ligand ...

  • Business Wire21 days ago

    GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018

    GlycoMimetics, Inc. (GLYC) announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2018 financial results on Friday, November 2, 2018, at 8:30 a.m. ET. To access the live audio webcast, or the subsequent archived recording, visit the “Investors - Events & Presentations” section of the GlycoMimetics website at www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.

  • Business Wire23 days ago

    GlycoMimetics to Present at Upcoming Investor Conferences

    GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at two upcoming investor conferences, as follows:

  • GlobeNewswire3 months ago

    Research Report Identifies FS Investment, Rush Enterprises, GlycoMimetics, Federal Signal, ATN International, and Novavax with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FS ...

  • Business Wire3 months ago

    GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)

    GlycoMimetics, Inc. (GLYC), a biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates to treat rare diseases, announced today that the Japan Patent Office (JPO) has issued Patent No. 6366150, for uproleselan (GMI-1271). The newly issued patent covers uproleselan’s composition of matter as well as pharmaceutical formulations, and expires in December 2032. “The JPO’s issuance of a patent for uproleselan extends major market intellectual property coverage for this E-selectin antagonist drug candidate,” stated Rachel King, GlycoMimetics’ Chief Executive Officer.

  • ACCESSWIRE3 months ago

    GlycoMimetics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 10, 2018 / GlycoMimetics, Inc. (NASDAQ: GLYC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 10, 2018 at 8:30 AM Eastern Time. ...

  • Business Wire3 months ago

    GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements

    ROCKVILLE, Md.-- -- Announced a Cooperative Research and Development Agreement to collaborate with the National Cancer Institute and the Alliance for Clinical Trials in Oncology to fund a planned pivotal Phase 3 trial to evaluate uproleselan in older, newly diagnosed acute myeloid leukemia patients eligible for intensive chemotherapy Continued to select new clinical sites and ready previously-selected ...

  • Business Wire3 months ago

    GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018

    GlycoMimetics, Inc. (GLYC) announced today that it will report its second quarter 2018 financial results on Thursday August 9, 2018, and will host a conference call and webcast on Friday, August 10, 2018, at 8:30 a.m. ET. To access the live audio webcast, or the subsequent archived recording, visit the “Investors - Events & Presentations” section of the GlycoMimetics website at www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.

  • ACCESSWIRE4 months ago

    Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration. Gains were broad based as six out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: GlycoMimetics Inc. (NASDAQ: GLYC), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).

  • ACCESSWIRE5 months ago

    Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities

    On Wednesday, June 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Geron Corp. (NASDAQ: GERN), Gilead Sciences Inc. (NASDAQ: GILD), Global Blood Therapeutics Inc. (NASDAQ: GBT), and GlycoMimetics Inc. (NASDAQ: GLYC).

  • Business Wire6 months ago

    GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference

    GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies Annual Health Care Conference in New York, on Thursday, June 7, 2018, at 11:30 a.m.

  • Business Wire6 months ago

    GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy

    GlycoMimetics, Inc. (GLYC), a biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates to treat rare diseases, announced today it had signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Under the terms of the CRADA, GlycoMimetics will collaborate with both the NCI and the Alliance for Clinical Trials in Oncology to conduct a randomized, controlled clinical trial testing the addition of GMI-1271 to a standard cytarabine/daunorubicin regimen (7&3) in older adults with previously untreated acute myelogenous leukemia (AML) who are suitable for intensive chemotherapy.

  • Business Wire7 months ago

    GlycoMimetics Reports First Quarter 2018 Results

    GlycoMimetics, Inc. today reported its financial results for the first quarter ended March 31, 2018 and highlighted recent company achievements. Quarter-end cash as a result of a follow-on financing in March was $242.6 million.

  • Business Wire7 months ago

    GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018

    GlycoMimetics, Inc. (GLYC) announced today that it will host a conference call and webcast to report its first quarter 2018 financial results on Thursday, May 3, 2018, at 8:30 a.m. ET. To access the live audio webcast, or the subsequent archived recording, visit the “Investors - Events & Presentations” section of the GlycoMimetics website at www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.

  • Business Wire8 months ago

    GlycoMimetics Announces Pricing of Public Offering of Common Stock

    GlycoMimetics, Inc. , a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $17.00 per share.

  • Business Wire8 months ago

    GlycoMimetics Announces Proposed Public Offering of Common Stock

    GlycoMimetics, Inc. , a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, 4,500,000 shares of its common stock in an underwritten public offering.

  • Business Wire8 months ago

    GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018

    GlycoMimetics, Inc. announced today that preclinical research suggesting the potential of two of its drug candidates, GMI-1271 and GMI-1359, as treatments for acute myeloid leukemia , metastasis in osteosarcoma and other cancers will be shared via poster presentations at the American Association for Cancer Research Annual Meeting 2018 in Chicago.

  • Business Wire8 months ago

    GlycoMimetics to Present at Four Investor Conferences This Month

    GlycoMimetics, Inc. announced today that it will present at four investor conferences during the month of March, including:

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Trending Tickers: GlycoMimetics, Inc. and Vericel Corporation

    NEW YORK, NY / ACCESSWIRE / March 6, 2018 / U.S. markets rallied Monday, with the Dow breaking a streak of 4 consecutive losses, as concerns over a potential trade war eased. The Dow Jones Industrial Average ...

  • Business Wire8 months ago

    GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results

    GlycoMimetics, Inc. today reported progress on its clinical development programs and its financial results for the fourth quarter and year ended December 31, 2017.